Tax Inversion Puts These 3 Mutual Funds in Focus - Best of Funds
Zacks Equity Research - Zacks Investment Research - Wed Jul 30, 1:38PM CDT
The trend of tax inversion has been mostly prevalent in the healthcare sector. Medical devices and pharma companies are rapidly buying foreign competitors. Mutual funds holding these stocks in their portfolio should thus experience solid uplift in the near term.
XPH, AKRX, PRGO, QCOR: ETF Outflow Alert
ETFChannel.com - Mon Jul 28, 10:29AM CDT
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR S&P Pharmaceuticals ETF where we have detected an approximate $44.5 million dollar outflow -- that's a 4.8%...
XPH Crushing the Pharma ETFs Competition - ETF News And Commentary
Sweta Killa - Zacks Investment Research - Fri Jun 20, 1:00PM CDT
This ETF is considered a solid pick given its strong fundamentals and the growing pharma space.
OxySure's Improving Financials & Operational Milestones Paint a Bullish Picture
ACCESSWIRE - Mon Mar 10, 8:01AM CDT
Whitefish, MT / March 10, 2014 / The healthcare industry has been attracting record amounts of capital in 2014, driven by biotechnology and pharmaceutical companies bringing new products to market. In fact, more than half of all money flowing into U.S. sector-focused ETFs, or $4.06 billion through February 28th, was placed in healthcare ETFs, according to data compiled by Bloomberg.
3 Pharma ETFs Beating the Market - ETF News And Commentary
Zacks Equity Research - Zacks Investment Research - Thu Feb 27, 11:00AM CST
Pharma ETFs continue their strong momentum this year too after an impressive performance in 2013.
Top Ranked Healthcare ETF in Focus: XPH - ETF News And Commentary
Zacks Equity Research - Zacks Investment Research - Wed Feb 12, 7:01AM CST
This top ranked fund could be a great way to target the strength in the health care market.
Obamacare Boosts Health Funds
at The Street - Mon Jan 27, 10:26AM CST
Pharmaceutical and hospital stocks rally as more consumers gain insurance.
SPDR S&P Pharmaceuticals ETF Up 31.8% Since SmarTrend Uptrend Call (XPH)
Comtex SmarTrend(R) - Wed Jan 22, 4:47PM CST
SmarTrend identified an Uptrend for SPDR S&P Pharmaceuticals ETF (AMEX:XPH) on July 1st, 2013 at $71.31. In approximately 7 months, SPDR S&P Pharmaceuticals ETF has returned 31.78% as of today's recent price of $93.97.
SPDR S&P Pharmaceuticals ETF Shares Up 30.6% Since SmarTrend's Buy Recommendation (XPH)
Comtex SmarTrend(R) - Wed Jan 15, 11:01AM CST
SmarTrend identified an Uptrend for SPDR S&P Pharmaceuticals ETF (AMEX:XPH) on July 1st, 2013 at $71.31. In approximately 7 months, SPDR S&P Pharmaceuticals ETF has returned 30.58% as of today's recent price of $93.12.
SPDR S&P Pharmaceuticals ETF Up 23.4% Since SmarTrend Uptrend Call (XPH)
Comtex SmarTrend(R) - Tue Dec 31, 5:25PM CST
SmarTrend identified an Uptrend for SPDR S&P Pharmaceuticals ETF (AMEX:XPH) on July 1st, 2013 at $71.31. In approximately 6 months, SPDR S&P Pharmaceuticals ETF has returned 23.36% as of today's recent price of $87.97.
22.5% Return Seen to Date on SmarTrend SPDR S&P Pharmaceuticals ETF Call (XPH)
Comtex SmarTrend(R) - Tue Dec 24, 11:19AM CST
SmarTrend identified an Uptrend for SPDR S&P Pharmaceuticals ETF (AMEX:XPH) on July 1st, 2013 at $71.31. In approximately 6 months, SPDR S&P Pharmaceuticals ETF has returned 22.47% as of today's recent price of $87.33.
A Comprehensive Guide to Pharma ETFs - ETF News And Commentary
Zacks Equity Research - ZACKS - Thu Dec 19, 11:01AM CST
The pharma industry remains on the bullish trend after an excellent performance this year.
Uptrend Call Working As SPDR S&P Pharmaceuticals ETF Stock Rises 20.5% (XPH)
Comtex SmarTrend(R) - Tue Dec 17, 9:56AM CST
SmarTrend identified an Uptrend for SPDR S&P Pharmaceuticals ETF (AMEX:XPH) on July 1st, 2013 at $71.31. In approximately 6 months, SPDR S&P Pharmaceuticals ETF has returned 20.52% as of today's recent price of $85.95.
How to Know if You Are Really a 'Value' Investor
at The Street - Wed Dec 11, 10:32AM CST
How many of us truly have the stomach or temperament for investing in the most hated of asset classes?